Milestone! World's First Ovarian Dual Activation Technology Assists Patients in Conception
Release time:
2025-01-15
Recently, a major breakthrough in the field of reproductive health has garnered wide attention. The "ovarian dual activation" technology, collaboratively developed by the Yinfeng Life Sciences Research Institute (referred to as "Yinfeng Life Sciences") and the team of Professor Wang Huiying and Dr. Jin Bo from the Shenzhen Hospital of Beijing University of Chinese Medicine (referred to as "the hospital"), has achieved another milestone in cryobiomedical technology. Using methods of "cryopreservation + PFC", this technology has helped two patients achieve natural conception, providing new hope for women of childbearing age who are cancer patients, infertile, or of advanced maternal age.
This is reportedly the first global instance of using this method for ovarian activation and achieving successful natural conception. The application of this technology not only brings blessings to patients with premature ovarian insufficiency and infertility but also offers a novel solution for preserving the fertility of female cancer patients of childbearing age. In China, at least one million children and women of childbearing age face the risk of iatrogenic premature ovarian insufficiency annually. Currently, ovarian tissue cryopreservation and transplantation are regarded as one of the most promising fertility preservation methods internationally.
World's First Ovarian Dual Activation Technology Assists Two Patients in Natural Conception
The team innovatively combined the in vitro cryo-activation technology (IVA) of primordial follicles with the platelet-free plasma (PFC) technology extracted from autologous veins, providing a safer, more effective, and personalized treatment solution for patients with premature ovarian insufficiency (POI) and poor ovarian response (POR).
Traditional IVA technology processes ovarian tissues externally using drug or non-drug methods; however, it presents issues like damaging primordial follicle DNA, low safety, and activation efficiency. The Yinfeng Life Sciences along with the team led by Wang Huiying and Jin Bo from the hospital applied several innovative technologies, adopting in vitro vitrification cryo-activation of ovarian tissues combined with the dual activation of PFC, establishing a new, safe, and effective technology for activating primordial follicles.
PFC technology employs special methods to concentrate, activate, and separate various growth factors, cytokines, and related proteins from autologous venous blood, followed by freeze-drying and other standardized preparation processes. Clinical studies have proven these endogenous growth factors and cytokines can aid tissue regeneration, including activating dormant primordial follicles, promoting angiogenesis, and increasing ovarian volume.
For POI/POR patients, follicles in the ovaries are difficult to activate and grow using traditional methods. The team's innovative IVA technology involves taking a small piece of ovarian cortical tissue via laparoscopic surgery, employing low-temperature cryo-revival technology for low-temperature activation processing in the laboratory. About an hour later, the tissue is transplanted in situ, making the previously atrophied ovarian tissue soft and supple again. Postoperative assessments showed improvements in ovarian volume, follicle count, and ovarian arterial blood flow, with hormone levels returning to normal.
Currently, the team has performed PFC ovarian activation on over 300 POI/POR patients and conducted data analyses on 11 cases of ovarian tissue cryo-activation technology. Results indicated the technology significantly improved ovarian function in patients, activated dormant follicles, and partially restored fertility. Among the 11 cases of ovarian tissue cryo-activation transplantation, two patients successfully achieved natural conception after three months of treatment.
Ovarian Cryo-Activation: Cryogenic Technology Safeguards Female Fertility
Experts note that the ovarian dual activation technology not only provides a safe and reliable new technology for POI/POR patients but also offers options for fertility preservation in cancer patients.
Fertility preservation, in essence, is a comprehensive solution integrating surgery, drugs, and laboratory technologies, aiming to protect human reproductive capabilities and ensure the continuous inheritance of genetic information. For women, fertility preservation mainly covers oocyte freezing, embryo freezing, and ovarian tissue freezing techniques. For men, sperm freezing is the main method to preserve fertility. Ovarian tissue cryopreservation and transplantation are currently seen as the most promising fertility preservation methods internationally, serving as the sole fertility preservation method for prepubescent girls and women of childbearing age who cannot delay cancer treatment.
The technology also shows potential for application in menopause management. By preserving part of the ovarian tissue at a young age through deep cryogenic preservation and transplanting it at an older age, menopause can be delayed, substituting hormone treatments and helping to slow down aging.
In the future, Yinfeng Life Sciences will collaborate with the Shenzhen Hospital of Beijing University of Chinese Medicine (Longgang) to continue original technological research in "fertility preservation technology," aiming to establish a complete and comprehensive fertility preservation system, extensively and effectively applying cryopreservation technology in clinical fertility preservation, contributing to building a fertility-friendly society.
We have reason to believe that cryobiomedical technology will become increasingly mature in larger scales, involving more complex organs and complete life forms. Whether in terms of "walking upright" in time or future Mars colonization, the development prospects of cryobiomedical technology deserve our shared anticipation.
Previous article
Previous article
Latest developments
In January 2025, members of the Yinfeng cryomedicine team actively participated in the "Sino-French Aerial Emergency Medical Rescue Training" and obtained certification. This signifies a further enhancement of the team's professional capabilities in the field of international emergency medical rescue.
Brands are an important symbol of high-quality development. Under the drive of strategies such as Brand Strong Province and Good Products Shandong, Shandong brands have risen to prominence. Particularly in recent years, Shandong brands have focused on new quality productivity, using "new" to enhance quality, achieving remarkable results in high-quality development.
With infinite hope for future medical technology, I applied to become a member of the Yinfeng Life Extension Program and volunteered to contribute to cryobiology in a hundred years by becoming a cryonics volunteer. I also believe that preservation in China is safer.
As a distinguished emblem of technological innovation in Shandong, Yinfeng's Life Continuation Project will continue to build a bridge for domestic and international government research and academic exchange, continually strengthen scientific collaborations and result transformations with global research institutions, consistently contribute to the development of cryobiomedicine, and inject continuous hope into the shared ideal of extending human life.
Yinfeng Life Continuation Plan
Address: Yinfeng Biotechnology Park, 1758 Gangyuan 6th Road, High-tech Zone, Jinan City, Shandong Province
Zip Code: 250102
Telephone: 0086-0531-88897351
Mobile: 0086-19953155507
Mobile website
Official WeChat Public Number
Links:Red Cross Society of China丨Shandong Red Cross Society丨Shandong Provincial Health Commission | Yinfeng Group| Yinfeng Biological Group
All rights reserved©Yinfeng Life Continuation Powered by www.300.cn SEO
